Published in J Virol on October 31, 2007
A prospective analysis of the Ab response to Plasmodium falciparum before and after a malaria season by protein microarray. Proc Natl Acad Sci U S A (2010) 2.90
Profiling humoral immune responses to P. falciparum infection with protein microarrays. Proteomics (2008) 2.43
A Burkholderia pseudomallei protein microarray reveals serodiagnostic and cross-reactive antigens. Proc Natl Acad Sci U S A (2009) 2.10
Heavily isotype-dependent protective activities of human antibodies against vaccinia virus extracellular virion antigen B5. J Virol (2009) 1.69
Rapid identification of monospecific monoclonal antibodies using a human proteome microarray. Mol Cell Proteomics (2012) 1.65
Vaccinia virus vaccines: past, present and future. Antiviral Res (2009) 1.58
Vaccinia virus extracellular enveloped virion neutralization in vitro and protection in vivo depend on complement. J Virol (2008) 1.49
Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus. Proc Natl Acad Sci U S A (2008) 1.31
An extremely diverse CD4 response to vaccinia virus in humans is revealed by proteome-wide T-cell profiling. J Virol (2008) 1.27
Identification of a common immune signature in murine and human systemic Salmonellosis. Proc Natl Acad Sci U S A (2012) 1.25
The stability and complexity of antibody responses to the major surface antigen of Plasmodium falciparum are associated with age in a malaria endemic area. Mol Cell Proteomics (2011) 1.24
Evaluation of smallpox vaccines using variola neutralization. J Gen Virol (2009) 1.21
The immunology of smallpox vaccines. Curr Opin Immunol (2009) 1.10
Plasmodium immunomics. Int J Parasitol (2010) 1.09
Uncovering the interplay between CD8, CD4 and antibody responses to complex pathogens. Future Microbiol (2010) 1.07
Evaluation of the efficacy of modified vaccinia Ankara (MVA)/IMVAMUNE against aerosolized rabbitpox virus in a rabbit model. Vaccine (2009) 1.06
Defining the humoral immune response to infectious agents using high-density protein microarrays. Future Microbiol (2010) 1.06
Generation and characterization of a large panel of murine monoclonal antibodies against vaccinia virus. Virology (2010) 1.05
Identification of the feline humoral immune response to Bartonella henselae infection by protein microarray. PLoS One (2010) 1.03
The evolution of poxvirus vaccines. Viruses (2015) 1.02
Vaccinia virus strain NYVAC induces substantially lower and qualitatively different human antibody responses compared with strains Lister and Dryvax. J Gen Virol (2008) 1.01
Genome-wide profiling of humoral immune response to Coxiella burnetii infection by protein microarray. Proteomics (2010) 1.01
High-throughput profiling of the humoral immune responses against thirteen human papillomavirus types by proteome microarrays. Virology (2010) 0.99
Poxvirus proteomics and virus-host protein interactions. Microbiol Mol Biol Rev (2009) 0.98
Human immune responses to Burkholderia pseudomallei characterized by protein microarray analysis. J Infect Dis (2011) 0.96
Applications of protein microarrays for biomarker discovery. Proteomics Clin Appl (2008) 0.96
Immunosignatures can predict vaccine efficacy. Proc Natl Acad Sci U S A (2013) 0.93
ORFeome approach to the clonal, HLA allele-specific CD4 T-cell response to a complex pathogen in humans. J Immunol Methods (2009) 0.91
Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategies. PLoS One (2009) 0.90
GM-CSF production allows the identification of immunoprevalent antigens recognized by human CD4+ T cells following smallpox vaccination. PLoS One (2011) 0.90
The top five "game changers" in vaccinology: toward rational and directed vaccine development. OMICS (2011) 0.88
Deletion of specific immune-modulatory genes from modified vaccinia virus Ankara-based HIV vaccines engenders improved immunogenicity in rhesus macaques. J Virol (2012) 0.87
Vaccinia virus encodes I5, a small hydrophobic virion membrane protein that enhances replication and virulence in mice. J Virol (2008) 0.87
The D10 decapping enzyme of vaccinia virus contributes to decay of cellular and viral mRNAs and to virulence in mice. J Virol (2013) 0.87
Multidimensional glycan arrays for enhanced antibody profiling. Mol Biosyst (2010) 0.86
Measurement of naturally acquired humoral immune responses against the C-terminal region of the Plasmodium vivax MSP1 protein using protein arrays. Parasitol Res (2011) 0.86
Characterization of monoclonal antibody's binding kinetics using oblique-incidence reflectivity difference approach. MAbs (2015) 0.86
The heterogeneity of human antibody responses to vaccinia virus revealed through use of focused protein arrays. Vaccine (2009) 0.85
Proteomic identification of immunodominant chlamydial antigens in a mouse model. J Proteomics (2012) 0.84
Measurement of antibody responses to Modified Vaccinia virus Ankara (MVA) and Dryvax(®) using proteome microarrays and development of recombinant protein ELISAs. Vaccine (2011) 0.84
Inferring epitopes of a polymorphic antigen amidst broadly cross-reactive antibodies using protein microarrays: a study of OspC proteins of Borrelia burgdorferi. PLoS One (2013) 0.84
Failure of the smallpox vaccine to develop a skin lesion in vaccinia virus-naïve individuals is related to differences in antibody profiles before vaccination, not after. Clin Vaccine Immunol (2012) 0.83
Predicting antigenicity of proteins in a bacterial proteome; a protein microarray and naïve Bayes classification approach. Chem Biodivers (2012) 0.82
Humoral immunity to smallpox vaccines and monkeypox virus challenge: proteomic assessment and clinical correlations. J Virol (2012) 0.82
Unusual features of vaccinia virus extracellular virion form neutralization resistance revealed in human antibody responses to the smallpox vaccine. J Virol (2012) 0.82
An approach to the identification of T cell epitopes in the genomic era: application to Francisella tularensis. Immunol Res (2009) 0.82
Whole genome identification of C. trachomatis immunodominant antigens after genital tract infections and effect of antibiotic treatment of pigtailed macaques. J Proteomics (2014) 0.81
The identification of HLA class II-restricted T cell epitopes to vaccinia virus membrane proteins. Virology (2010) 0.81
Retrograde Transport from Early Endosomes to the trans-Golgi Network Enables Membrane Wrapping and Egress of Vaccinia Virus Virions. J Virol (2016) 0.80
Large screen approaches to identify novel malaria vaccine candidates. Vaccine (2015) 0.80
The neutralizing antibody response to the vaccinia virus A28 protein is specifically enhanced by its association with the H2 protein. Virology (2010) 0.79
A broadly applicable approach to T cell epitope identification: application to improving tumor associated epitopes and identifying epitopes in complex pathogens. J Immunol Methods (2011) 0.78
A systems biology approach for diagnostic and vaccine antigen discovery in tropical infectious diseases. Curr Opin Infect Dis (2015) 0.78
Protein microarrays and biomarkers of infectious disease. Int J Mol Sci (2010) 0.78
T cell antigen discovery using soluble vaccinia proteome reveals recognition of antigens with both virion and nonvirion association. J Immunol (2014) 0.77
Enhancement of immune response to an antigen delivered by vaccinia virus by displaying the antigen on the surface of intracellular mature virion. Vaccine (2011) 0.77
Opposing Roles of Double-Stranded RNA Effector Pathways and Viral Defense Proteins Revealed with CRISPR-Cas9 Knockout Cell Lines and Vaccinia Virus Mutants. J Virol (2016) 0.76
The impact of "omic" and imaging technologies on assessing the host immune response to biodefence agents. J Immunol Res (2014) 0.75
Development of eczema vaccinatum in atopic mouse models and efficacy of MVA vaccination against lethal poxviral infection. PLoS One (2014) 0.75
Deletion of the Vaccinia Virus I2 Protein Interrupts Virion Morphogenesis, Leading to Retention of the Scaffold Protein and Mislocalization of Membrane-Associated Entry Proteins. J Virol (2017) 0.75
Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci U S A (1992) 4.58
The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology (1998) 4.13
Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J Gen Virol (1991) 3.83
Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature (2004) 3.65
Profiling the humoral immune response to infection by using proteome microarrays: high-throughput vaccine and diagnostic antigen discovery. Proc Natl Acad Sci U S A (2005) 3.59
Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc Natl Acad Sci U S A (1996) 3.29
Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses. Proc Natl Acad Sci U S A (2003) 3.18
Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. Virology (1997) 3.17
Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge. Proc Natl Acad Sci U S A (2004) 3.08
[The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author's transl)]. Zentralbl Bakteriol B (1978) 2.92
Immunity and immunological memory following smallpox vaccination. Immunol Rev (2006) 2.57
Vaccinia virus proteome: identification of proteins in vaccinia virus intracellular mature virion particles. J Virol (2006) 2.38
A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine (1994) 2.22
Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus. J Virol (2005) 2.11
Proteome-wide analysis of the serological response to vaccinia and smallpox. Proteomics (2007) 2.10
Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates. Virology (2003) 2.07
Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques. Vaccine (2001) 2.06
Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine. Vaccine (2005) 1.94
Protein composition of the vaccinia virus mature virion. Virology (2006) 1.93
Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T cells and comparative analysis of smallpox vaccines. Proc Natl Acad Sci U S A (2002) 1.85
Development and use of a vaccinia virus neutralization assay based on flow cytometric detection of green fluorescent protein. J Virol (2003) 1.73
Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naïve and vaccinia-immune individuals. Vaccine (2006) 1.71
Pox proteomics: mass spectrometry analysis and identification of Vaccinia virion proteins. Virol J (2006) 1.69
Clinical and immunologic responses to multiple doses of IMVAMUNE (Modified Vaccinia Ankara) followed by Dryvax challenge. Vaccine (2007) 1.67
Improved assay to detect neutralizing antibody following vaccination with diluted or undiluted vaccinia (Dryvax) vaccine. J Clin Microbiol (2003) 1.63
The exit of vaccinia virus from infected cells. Virus Res (2004) 1.46
Extracellular enveloped vaccinia virus. Entry, egress, and evasion. Adv Exp Med Biol (1998) 1.32
Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model. Vaccine (1997) 1.32
Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model. Virology (2005) 1.31
Identification and preliminary characterization of vaccinia virus (Dryvax) antigens recognized by vaccinia immune globulin. Virology (2005) 1.26
Activity of vaccinia virus-neutralizing antibody in the sera of smallpox vaccinees. Microbes Infect (2005) 1.20
Modified vaccinia virus Ankara immunization protects against lethal challenge with recombinant vaccinia virus expressing murine interleukin-4. J Virol (2004) 1.05
Comparative efficacy of modified vaccinia Ankara (MVA) as a potential replacement smallpox vaccine. Vaccine (2006) 0.98
Adverse reactions after smallpox vaccination. Med J Aust (1977) 0.97
Comparative efficacy of replicating smallpox vaccine strains in a murine challenge model. Vaccine (2005) 0.93
Protection induced in mice against a lethal orthopox virus by the Lister strain of vaccinia virus and modified vaccinia virus Ankara (MVA). Vaccine (2006) 0.91
Serum antibody responses after intradermal vaccination against influenza. N Engl J Med (2004) 4.88
Clinical responses to undiluted and diluted smallpox vaccine. N Engl J Med (2002) 3.86
A role for tumor necrosis factor receptor-2 and receptor-interacting protein in programmed necrosis and antiviral responses. J Biol Chem (2003) 3.70
Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature (2004) 3.65
Profiling the humoral immune response to infection by using proteome microarrays: high-throughput vaccine and diagnostic antigen discovery. Proc Natl Acad Sci U S A (2005) 3.59
Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses. Proc Natl Acad Sci U S A (2003) 3.18
Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge. Proc Natl Acad Sci U S A (2004) 3.08
Colocalization of transcription and translation within cytoplasmic poxvirus factories coordinates viral expression and subjugates host functions. Cell Host Microbe (2007) 2.97
A prospective analysis of the Ab response to Plasmodium falciparum before and after a malaria season by protein microarray. Proc Natl Acad Sci U S A (2010) 2.90
Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys. Cell (2013) 2.88
Overcoming immunity to a viral vaccine by DNA priming before vector boosting. J Virol (2003) 2.67
Adjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissues. J Infect Dis (2010) 2.64
Age-associated decrease in TLR function in primary human dendritic cells predicts influenza vaccine response. J Immunol (2010) 2.63
Dose-related effects of smallpox vaccine. N Engl J Med (2002) 2.55
Selective CD4+ T cell help for antibody responses to a large viral pathogen: deterministic linkage of specificities. Immunity (2008) 2.43
Profiling humoral immune responses to P. falciparum infection with protein microarrays. Proteomics (2008) 2.43
Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc Natl Acad Sci U S A (2004) 2.38
The immunogenetics of smallpox vaccination. J Infect Dis (2007) 2.23
Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions. J Virol (2004) 2.21
Complete pathway for protein disulfide bond formation encoded by poxviruses. Proc Natl Acad Sci U S A (2002) 2.19
Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice. J Virol (2005) 2.18
A genome-wide proteome array reveals a limited set of immunogens in natural infections of humans and white-footed mice with Borrelia burgdorferi. Infect Immun (2008) 2.15
Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine. J Virol (2002) 2.13
Dynamic antibody responses to the Mycobacterium tuberculosis proteome. Proc Natl Acad Sci U S A (2010) 2.12
Proteome-wide analysis of the serological response to vaccinia and smallpox. Proteomics (2007) 2.10
A Burkholderia pseudomallei protein microarray reveals serodiagnostic and cross-reactive antigens. Proc Natl Acad Sci U S A (2009) 2.10
Poxvirus multiprotein entry-fusion complex. Proc Natl Acad Sci U S A (2005) 2.09
Vaccinia virus entry into cells is dependent on a virion surface protein encoded by the A28L gene. J Virol (2004) 2.06
A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers. J Infect Dis (2011) 1.99
AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial. Lancet Infect Dis (2013) 1.95
Vaccinia virus entry into cells via a low-pH-dependent endosomal pathway. J Virol (2006) 1.94
Protein composition of the vaccinia virus mature virion. Virology (2006) 1.93
Vaccinia virus H2 protein is an essential component of a complex involved in virus entry and cell-cell fusion. J Virol (2005) 1.88
Vaccinia virus A21 virion membrane protein is required for cell entry and fusion. J Virol (2005) 1.86
Immunodominant Francisella tularensis antigens identified using proteome microarray. Proteomics (2007) 1.85
Flow-cytometric detection of vaccinia-induced memory effector CD4(+), CD8(+), and gamma delta TCR(+) T cells capable of antigen-specific expansion and effector functions. J Infect Dis (2005) 1.84
HIV-1 DNA/MVA vaccination reduces the per exposure probability of infection during repeated mucosal SHIV challenges. Virology (2006) 1.83
Redundancy and plasticity of neutralizing antibody responses are cornerstone attributes of the human immune response to the smallpox vaccine. J Virol (2008) 1.77
Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara. J Infect Dis (2008) 1.77
Prevention of infection by a granulocyte-macrophage colony-stimulating factor co-expressing DNA/modified vaccinia Ankara simian immunodeficiency virus vaccine. J Infect Dis (2011) 1.76
Discovery of antivirals against smallpox. Proc Natl Acad Sci U S A (2004) 1.76
Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial. J Acquir Immune Defic Syndr (2007) 1.73
The product of the vaccinia virus L5R gene is a fourth membrane protein encoded by all poxviruses that is required for cell entry and cell-cell fusion. J Virol (2005) 1.73
Development and use of a vaccinia virus neutralization assay based on flow cytometric detection of green fluorescent protein. J Virol (2003) 1.73
Simultaneous high-resolution analysis of vaccinia virus and host cell transcriptomes by deep RNA sequencing. Proc Natl Acad Sci U S A (2010) 1.72
Hemoglobin S and C heterozygosity enhances neither the magnitude nor breadth of antibody responses to a diverse array of Plasmodium falciparum antigens. J Infect Dis (2011) 1.71
Oligomeric structure of the human immunodeficiency virus type 1 envelope protein on the virion surface. J Virol (2002) 1.69
Attenuated poxvirus-based simian immunodeficiency virus (SIV) vaccines given in infancy partially protect infant and juvenile macaques against repeated oral challenge with virulent SIV. J Acquir Immune Defic Syndr (2005) 1.68
From protein microarrays to diagnostic antigen discovery: a study of the pathogen Francisella tularensis. Bioinformatics (2007) 1.68
Clinical and immunologic responses to multiple doses of IMVAMUNE (Modified Vaccinia Ankara) followed by Dryvax challenge. Vaccine (2007) 1.67
Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. J Infect Dis (2011) 1.67
Identification of humoral immune responses in protein microarrays using DNA microarray data analysis techniques. Bioinformatics (2006) 1.65
Entry of vaccinia virus and cell-cell fusion require a highly conserved cysteine-rich membrane protein encoded by the A16L gene. J Virol (2006) 1.63
Improved assay to detect neutralizing antibody following vaccination with diluted or undiluted vaccinia (Dryvax) vaccine. J Clin Microbiol (2003) 1.63
Vaccinia virus A28L gene encodes an essential protein component of the virion membrane with intramolecular disulfide bonds formed by the viral cytoplasmic redox pathway. J Virol (2004) 1.62
Response to smallpox vaccine in persons immunized in the distant past. JAMA (2003) 1.59
Role of the I7 protein in proteolytic processing of vaccinia virus membrane and core components. J Virol (2004) 1.59
Comparative immunogenicity of trivalent influenza vaccine administered by intradermal or intramuscular route in healthy adults. Vaccine (2007) 1.58
Highly effective control of an AIDS virus challenge in macaques by using vesicular stomatitis virus and modified vaccinia virus Ankara vaccine vectors in a single-boost protocol. J Virol (2004) 1.58
Prevaccine determination of the expression of costimulatory B7 molecules in activated monocytes predicts influenza vaccine responses in young and older adults. J Infect Dis (2007) 1.56
External scaffold of spherical immature poxvirus particles is made of protein trimers, forming a honeycomb lattice. J Cell Biol (2005) 1.55
Sterile protective immunity to malaria is associated with a panel of novel P. falciparum antigens. Mol Cell Proteomics (2011) 1.53
Immunization of newborn rhesus macaques with simian immunodeficiency virus (SIV) vaccines prolongs survival after oral challenge with virulent SIVmac251. J Virol (2003) 1.53
Antigen-specific acquired immunity in human brucellosis: implications for diagnosis, prognosis, and vaccine development. Front Cell Infect Microbiol (2012) 1.52
GM-CSF DNA: an adjuvant for higher avidity IgG, rectal IgA, and increased protection against the acute phase of a SHIV-89.6P challenge by a DNA/MVA immunodeficiency virus vaccine. Virology (2007) 1.52
Physical and immunological characterization of a recombinant secreted form of the membrane protein encoded by the vaccinia virus L1R gene. Virology (2005) 1.49
Safety and immunogenicity of LC16m8, an attenuated smallpox vaccine in vaccinia-naive adults. J Infect Dis (2011) 1.48
Vaccinia virus F9 virion membrane protein is required for entry but not virus assembly, in contrast to the related L1 protein. J Virol (2006) 1.45
Epitope-mapping studies define two major neutralization sites on the vaccinia virus extracellular enveloped virus glycoprotein B5R. J Virol (2005) 1.44
Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model. Virology (2002) 1.44